p53 mutation and cyclin D1 amplification correlate with cisplatin sensitivity in xenografted human squamous cell carcinomas from head and neck

References

• Cognetti F, Pinnaro P, Ruggeri EM, Carlini P, Perrino A, Impiombata FA, et al. Prognostic factors for chemotherapy response and survival using combination chemotherapy as initial treatment of advanced head and neck squamous cell cancer. J Clin Oncol 1989; 7: 829–37
   PubMed Web of Science ®Google Scholar
• Beauvillain C, Mahe M, Bourdin S, Peuvrel P, Bergerot P, Riviere A, et al. Final results of a randomized trial comparing chemotherapy plus radiotherapy with chemotherapy plus surgery plus radiotherapy in locally advanced resectable hypopharyngeal carcinomas. Laryngoscope 1997; 107: 648–53
   PubMed Web of Science ®Google Scholar
• Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000; 356: 767–8
   PubMed Web of Science ®Google Scholar
• Bourhis J, Pignon JP. Meta-analyses in head and neck squamous cell carcinoma. Hematology/Oncology clinics of North America 1999; 13: 769–75
   PubMed Web of Science ®Google Scholar
• Kartalou M, Essigmann J. Mechanism of resistance to cisplatin. Mutation Research 2001; 478: 23–43
   PubMed Web of Science ®Google Scholar
• Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323–31
   PubMed Web of Science ®Google Scholar
• Koch WM, Brennan JA, Zahurak M, Goodman SN, Westra WH, Schwab D, et al. p53 mutation and locoregional treatment failure in head and neck squamous carcinoma. J Natl Cancer Inst 1996; 6(88)1580–6
   Google Scholar
• Mineta H, Borg A, Dictor M, Wahlberg P, Akervall J, Wennerberg J. p53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma. Br J Cancer 1998; 78: 1084–90
   PubMed Web of Science ®Google Scholar
• Cabelguenne A, Blons H, de Waziers I, Carnot F, Houllier AM, Sousse, et al. P53 alterations predict tumour response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: A prospective series. J Clin Oncol 2000; 18: 1465–73
   PubMed Web of Science ®Google Scholar
• Bradford CR, Zhu S, Ogawa H, Ogawa T., Ubell M, Narayan A, et al. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck 2003; 25: 654–61
   PubMed Web of Science ®Google Scholar
• Åkervall J, Michalides R, Mineta H, Balm A, Borg Å, Dictor M, et al. Amplification of cyclin D1 in squamous cell carcinoma of head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer 1997; 79: 380–9
   PubMed Web of Science ®Google Scholar
• Åkervall J, Michalides R, Dictor M, Brun E, Balm F, Wennerberg J. Cyclin D1 overexpression versus response to induction chemotherapy in squamous cell carcinoma of the head and neck–preliminary report. Acta Oncol 2001; 40: 505–11
   PubMed Web of Science ®Google Scholar
• Ishiguro R, Fujii M, Yamashita T, Tashiro M, Tomita T, Ogawa K, et al. CCND1 amplification predicts sensitivity to chemotherapy and chemoradiotherapy in head and neck squamous cell carcinoma. Anticancer Res 2003; 23: 5213–20
   PubMed Web of Science ®Google Scholar
• Akervall J, Kurnit DM, Adams M, Zhu S, Fischer SG, Bradford CR, et al. Overexpression of cyclin D1 correlates with sensitivity to cisplatin in squamous cell carcinoma cell lines of head and neck. Acta Otolaryngol 2004; 124: 851–7
   PubMed Web of Science ®Google Scholar
• Marilene B, Wang MD, Helena T, Yip MD, Sriivatsan ES. Antisense cyclin D1 enhances sensitivity of head and neck cancer cells to cisplatin. Laryngoscope 2001; 111: 982–8
   PubMed Web of Science ®Google Scholar
• Wennerberg J. Changes in growth pattern of human squamous cell carcinomas of head and neck during serial passages in nude mice. Int J Cancer 1984; 33: 245–50
   PubMed Web of Science ®Google Scholar
• Steel G. Growth kinetics of tumours. Clarendon Press, Oxford 1977
   Google Scholar
• Lesser ML, Braun HI, Helson L. Statistical methods for measuring and comparing treatment efficacies: Applications to nude mice experimentation. Exp Cell Biol 1980; 48: 126–37
   PubMedGoogle Scholar
• Tanner MM, Karhu RA, Nupponen NN, Borg A, Baldetorp B, Pejovic T, et al. Genetic aberrations in hypodiploid breast cancer: Frequent loss of chromosome 4 and amplification of cyclin D1 oncogene. Am J Pathol 1998; 153: 191–9
   PubMed Web of Science ®Google Scholar
• Fioretos T, Strömbeck B, Sandberg T, Johansson B, Billström R, Borg Å, et al. Isochromosome 17q in blast crisis of chronic myeloid leukemia and in other hematologic malignancies is the result of clustered breakpoints in 17p11 and is not associated with coding TP53 mutations. Blood 1999; 94: 225–32
   PubMed Web of Science ®Google Scholar
• Manos MM, Ting J, Wright DK, Lewis AJ, Broker TR, Wollinsky SM. Use of polymerase chain reaction amplification for detection of human papillomaviruses. Cancer Cells 1989; 7: 209–14
   Google Scholar
• De Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. The use of general primers GP5 and GP6 elongated at their 6′ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 1995; 76: 1057–62
   PubMed Web of Science ®Google Scholar
• Raybaud-Diogene H, Fortin A, Morency R, Roy J, Monteil RA, Tetu B. Markers of radioresistance in squamous cell carcinomas of the head and neck: A clinicopathologic and immunohistochemical study. J Clin Oncol 1997; 15: 1030–8
   PubMed Web of Science ®Google Scholar
• Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807–10
   PubMed Web of Science ®Google Scholar
• Pekkola-Heino K, Servomaa K, Kiuru A, Grenman R. Increased radiosensitivity is associated with p53 mutations in cell lines derived from oral cavity carcinoma. Acta Otolaryngol 1996; 116: 341–4
   PubMed Web of Science ®Google Scholar
• Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003; 3: 387–402
   PubMed Web of Science ®Google Scholar
• Bartokova J, Lukas J, Muller H, Strauss M, Gusterson B, Bartek J. Abnormal patterns of D-type Cyclin expression and G1 regulation in human head and neck cancer. Cancer Res 1995; 55: 949–56
   PubMed Web of Science ®Google Scholar
• Hinds PW, Dowdy SF, Eaton EN, Arnold A, Weinberg RA. Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci U S A 1994; 91: 709–13
   PubMed Web of Science ®Google Scholar
• Sauter ER, Nesbit M, Litwin S, Klein-Szanto AJ, Cheffetz S, Herlyn M. Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinomas. Cancer Res 1999; 59: 4876–81
   PubMed Web of Science ®Google Scholar